Price:
Rs. 23,000.00
Sample Type: Tissue
Fasting Not Required
Notes:G8234
Frequently Asked Questions (FAQ's):
What does the Glioma Basic Panel include at Metropolis Healthcare?
It evaluates essential gene mutations associated with gliomas, helping clinicians understand tumor biology and guide treatment decisions.
How does Metropolis Healthcare perform this molecular test?
Metropolis Healthcare uses high-precision sequencing platforms and strict quality protocols to ensure reliable detection of clinically relevant glioma mutations.
Who should consider taking the Glioma Basic Panel?
Patients diagnosed with or suspected of having a brain tumor, especially gliomas, may benefit from this test to support accurate classification and management.
What type of sample is required at Metropolis Healthcare for this test?
Tumor tissue or extracted DNA, depending on clinical requirements, is typically used for molecular analysis at Metropolis Healthcare.
How long does it take to receive results from Metropolis Healthcare?
The reporting timeline varies based on tumor processing and sequencing, but Metropolis Healthcare provides detailed results within the standard molecular testing timeframe.
Does this panel help guide personalized treatment?
Yes, identifying specific tumor mutations assists clinicians in selecting targeted therapies and predicting treatment response.
Is this test useful for prognosis assessment?
Yes, certain mutations included in the panel are linked to prognosis, and Metropolis Healthcare provides expert interpretation to support clinical planning.
Can this test detect all types of brain tumor mutations?
It focuses on the most common and clinically relevant glioma-associated mutations; broader panels may be recommended for more extensive profiling.